Last reviewed · How we verify
Quadrivalent influenza GSK2282512A vaccine — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Quadrivalent influenza GSK2282512A vaccine (Quadrivalent influenza GSK2282512A vaccine) — GlaxoSmithKline. This quadrivalent influenza vaccine stimulates the body's immune system to produce antibodies against four different influenza viruses.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Quadrivalent influenza GSK2282512A vaccine TARGET | Quadrivalent influenza GSK2282512A vaccine | GlaxoSmithKline | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Quadrivalent influenza GSK2282512A vaccine CI watch — RSS
- Quadrivalent influenza GSK2282512A vaccine CI watch — Atom
- Quadrivalent influenza GSK2282512A vaccine CI watch — JSON
- Quadrivalent influenza GSK2282512A vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Quadrivalent influenza GSK2282512A vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/quadrivalent-influenza-gsk2282512a-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab